Corewell Health™

Patient Name	
DOB	
MRN	
Physician	
CSN	

Physician's Orders
RITUXIMAB OR BIOSIMILAR, EVERY 14 DAYS TIMES 2 DOSES - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER

Anticipated Infusion Date_____ ICD 10 Code with Description_____

Height_____(cm) Weight_____(kg) Allergies_____

Site of Service

☐ CH Gerber ☐ CH Lemmen Holton (GR) ☐ CH Pennock ☐ CH Greenville
☐ CH Helen DeVos (GR) ☐ CH Ludington ☐ CH Reed City ☐ CH Zeeland
☐ CH Blodgett (GR)

Provider Specialty

☐ Allergy/Immunology ☐ Infectious Disease ☐ OB/GYN ☐ Rheumatology
☐ Cardiology ☐ Internal Med/Family Practice ☐ Other ☐ Surgery
☐ Gastroenterology ☐ Nephrology ☐ Otolaryngology ☐ Urology
☐ Genetics ☐ Neurology ☐ Pulmonary ☐ Wound Care

Treatment Intent

☐ Conditioning ☐ Curative ☐ Mobilization ☐ Supportive
☐ Control ☐ Maintenance ☐ Palliative

Cycle 1

One dose every 14 days x 2 doses on day 1, 15

Provider Reminder

◉ **ONC PROVIDER REMINDER 2**

Confirm that the appropriate informed consents have been signed and are in the medical record.

Appointment Requests

◉ **ONCBCN CALCULATED LENGTH INFUSION APPOINTMENT REQUEST 1**

Safety Parameters and Special Instructions

◉ **ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 3**

RITUXIMAB DOSING INTERVAL - Rheumatoid arthritis: IV: 1,000 mg on days 1 and 15 (in combination with methotrexate); subsequent courses may be administered every 24 weeks (based on clinical evaluation), if necessary may be repeated no sooner than every 16 weeks

See dosing guidelines for other clinical indications as there variations in dosing interval depending on clinical indication.

Labs

◉ **COMPLETE BLOOD COUNT (CBC) W/DIFFERENTIAL**

■ **Pregnancy tests recommended for Females aged 12 to 60 with Uterus intact.**

Please order as appropriate for clinical presentation
Interval: Once Selection conditions: Patient could become pregnant

◯ **HCG, QUANTITATIVE**

■ **ONC PROVIDER REMINDER**

Review prior hepatitis labs and consider repeat screening as indicated.

■ **HEPATITIS PANEL**

Selection conditions: Hides NCCN Hepatitis Screening orders in background if the patient has had a completed hepatitis lab within the last 365 days.

■ **HEP B CORE TOTAL AB**

Selection conditions: Hides NCCN Hepatitis Screening orders in background if the patient has had a completed hepatitis lab within the last 365 days.

CONTINUED ON PAGE 2 ➔

NOTE: Epic Treatment/Therapy Plan Orders. To be scanned/attached to the appropriate Infusion Referral Order in Epic.

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

Corewell Health™

Patient Name
DOB
MRN
Physician
CSN

RITUXIMAB OR BIOSIMILAR, EVERY 14 DAYS TIMES 2 DOSES - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER *(CONTINUED)*

Page 2 to 4

Vitals

◉ **VITAL SIGNS**

RITUXIMAB - Dose 1 & 2: Vital signs every 15 minutes x 2 hours, then hourly throughout infusion. Subsequent doses: Vital signs with rate changes.

Nursing Orders

◉ **HYPERSENSITIVITY REACTION ADULT ONCOLOGY PROTOCOL**

◉ **ONC NURSING COMMUNICATION 100**

May Initiate IV Catheter Patency Adult Protocol

Treatment Parameters

◉ **ONC MONITORING AND HOLD PARAMETERS 3**

May proceed with treatment if hepatitis B core antibody and surface antigen labs have been resulted prior to the first dose, and the results are negative.

Pre-Medications

◯ **acetaminophen (Tylenol) tablet**

Dose: Route: Oral Once for 1 dose
☐ 325 mg ☐ 650 mg
☐ 500 mg ☐ 1000 mg
Instructions: Administer 30 minutes prior to rituximab.

◯ **diphenhydrAMINE (Benadryl) injection**

Dose: Route: Intravenous Once for 1 dose
☐ 25 mg
☐ 50 mg
Instructions: Administer 30 minutes prior to rituximab.

Pre-Medications

◉ **ONC PROVIDER REMINDER 7**

HISTORY OF INFUSION REACTION: consider adding CORTICOSTEROID pre-medication prior to riTUXimab or biosimilar

◯ **dexAMETHasone (Decadron) injection 10 mg**

Dose: 10 mg Route: Intravenous Once over 5 Minutes for 1 dose
Instructions:
For patient with a history of reaction to riTUXimab or biosimilar. Administer 30 minutes prior to start of riTUXimab or biosimilar.

◯ **methylPREDNISolone sodium succinate (SOLU-Medrol) injection 125 mg**

Dose: 125 mg Route: Intravenous Once for 1 dose
Instructions:
For patient with a history of reaction to riTUXimab or biosimilar. Administer 30 minutes prior to start of riTUXimab or biosimilar.

◯ **hydrocortisone sodium succinate (PF) (Solu-CORTEF) injection 100 mg**

Dose: 100 mg Route: Intravenous Once for 1 dose
Instructions:
For patient with a history of reaction to riTUXimab or biosimilar. Administer 30 minutes prior to start of riTUXimab or biosimilar.

Monoclonal Antibody / Biotherapy

◉ **riTUXimab-pvvr (RUXIENCE) 1,000 mg in sodium chloride 0.9% 500 mL (2 mg/mL) infusion**

Dose: 1,000 mg Route: Intravenous Titrate @ 25-200 mL/hr for 1 dose
Instructions:
Before start of riTUXimab-pvvr, infusion, prime 0.9% sodium chloride 250 mL with primary tubing and have available at bedside in case of hypersensitivity or infusion reaction. Do NOT connect this saline with any other intravenous drugs, fluids, or blood products.

Start infusion at 50 mg/hr (25 mL/hr). For patients tolerating the infusion well, the rate of

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

CONTINUED ON PAGE 3 ➔

Corewell Health™

Patient Name
DOB
MRN
Physician
CSN

RITUXIMAB OR BIOSIMILAR, EVERY 14 DAYS TIMES 2 DOSES - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER *(CONTINUED)*

infusion may be increased in increments of 50 mg/hr (25 mL/hr) at intervals of 30 minutes to a maximum rate of 400 mg/hr (200 mL/hr).

SUBSEQUENT INFUSIONS: If patient tolerated initial infusion, start at 100 mg/hour (50 mL/hr); if there is no infusion-related reaction, increase the rate by 100 mg/hour (50 mL/hr) increments every 30 minutes, to a maximum rate of 400 mg/hour (200 mL/hr)

◯ **riTUXimab-abbs (TRUXIMA) 1,000 mg in sodium chloride 0.9% 500 mL (2 mg/mL) infusion**

Dose: 1,000 mg Route: Intravenous Titrate @ 25-200 mL/hr for 1 dose

Instructions:

Before start of riTUXimab-abbs, infusion, prime 0.9% sodium chloride 250 mL with primary tubing and have available at bedside in case of hypersensitivity or infusion reaction. Do NOT connect this saline with any other intravenous drugs, fluids, or blood products.

Start infusion at 50 mg/hr (25 mL/hr). For patients tolerating the infusion well, the rate of infusion may be increased in increments of 50 mg/hr (25 mL/hr) at intervals of 30 minutes to a maximum rate of 400 mg/hr (200 mL/hr).

SUBSEQUENT INFUSIONS: If patient tolerated initial infusion, start at 100 mg/hour (50 mL/hr); if there is no infusion-related reaction, increase the rate by 100 mg/hour (50 mL/hr) increments every 30 minutes, to a maximum rate of 400 mg/hour (200 mL/hr)

◯ **riTUXimab (RITUXAN) 1,000 mg in sodium chloride 0.9% 500 mL (2 mg/mL) infusion**

Dose: 1,000 mg Route: Intravenous Titrate @ 25-200 mL/hr for 1 dose

Instructions:

Before start of riTUXimab, infusion, prime 0.9% sodium chloride 250 mL with primary tubing and have available at bedside in case of hypersensitivity or infusion reaction. Do NOT connect this saline with any other intravenous drugs, fluids, or blood products.

Start infusion at 50 mg/hr (25 mL/hr). For patients tolerating the infusion well, the rate of infusion may be increased in increments of 50 mg/hr (25 mL/hr) at intervals of 30 minutes to a maximum rate of 400 mg/hr (200 mL/hr).

SUBSEQUENT INFUSIONS: If patient tolerated initial infusion, start at 100 mg/hour (50 mL/hr); if there is no infusion-related reaction, increase the rate by 100 mg/hour (50 mL/hr) increments every 30 minutes, to a maximum rate of 400 mg/hour (200 mL/hr)

◯ **riTUXimab-arrx (RIABNI) 1,000 mg in sodium chloride 0.9% 500 mL (2 mg/mL) infusion**

Dose: 1,000 mg Route: Intravenous Titrate @ 25-200 mL/hr for 1 dose

Instructions:

Before start of riTUXimab-arrx infusion, prime 0.9% sodium chloride 250 mL with primary tubing and have available at bedside in case of hypersensitivity or infusion reaction. Do NOT connect this saline with any other intravenous drugs, fluids, or blood products.

Start infusion at 50 mg/hr (25 mL/hr). For patients tolerating the infusion well, the rate of infusion may be increased in increments of 50 mg/hr (25 mL/hr) at intervals of 30 minutes to a maximum rate of 400 mg/hr (200 mL/hr).

SUBSEQUENT INFUSIONS: If patient tolerated initial infusion, start at 100 mg/hour (50 mL/hr); if there is no infusion-related reaction, increase the rate by 100 mg/hour (50 mL/hr) increments every 30 minutes, to a maximum rate of 400 mg/hour (200 mL/hr)

Supportive Care

◉ **prochlorperazine (COMPAZINE) tablet 10 mg**

Dose: 10 mg Route: Oral Every 6 hours PRN

Instructions: Use 1st line for nausea/vomiting for patients able to tolerate oral medications.

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

CONTINUED ON PAGE 4 ➔

Corewell Health™

Patient Name	
DOB	
MRN	
Physician	
CSN	

RITUXIMAB OR BIOSIMILAR, EVERY 14 DAYS TIMES 2 DOSES - ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER *(CONTINUED)*

◉ **prochlorperazine (COMPAZINE) injection 10 mg**
Dose: 10 mg Route: Intravenous Every 6 hours PRN over 5 Minutes
Instructions: Use 1st line for nausea/vomiting for patients unable to tolerate oral medications.

◉ **ondansetron (ZOFRAN-ODT) disintegrating tablet 8 mg**
Dose: 8 mg Route: Oral Every 8 hours PRN
Instructions: Use 2nd line for Nausea/Vomiting. May give IV if unable to tolerate PO.

◉ **ondansetron (ZOFRAN) injection 8 mg**
Dose: 8 mg Route: Intravenous Every 8 hours PRN over 5 Minutes
Instructions: Use 2nd line for Nausea/Vomiting. May give IV if unable to tolerate PO.

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

Telephone order/Verbal order documented and read-back completed. Practitioner's initials _____

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		**VALIDATED:**		**ORDERED:**			
TIME	**DATE**	**TIME**	**DATE**	**TIME**	**DATE**	Pager #	
	Sign		**R.N. Sign**		**Physician Print**		**Physician Sign**

 © Corewell Health